MedTrace Logo

Zandelisib + Tazemetostat in R/R Follicular Lymphoma

NCT05604417 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2023-07-07

No results posted yet for this study

Summary

This research study is being done to estimate the safety and efficacy of zandelisib and tazemetostat in people with relapsed or refractory follicular lymphoma (FL)

This research study involves Zandelisib in combination with Tazemetostat.

MEI Pharma, Inc, a biotechnology company, is supporting this research study by providing funding for the research study, including the study drug zandelisib.

Conditions

  • Relapsed Follicular Lymphoma
  • Refractory Follicular Lymphoma

Interventions

DRUG

TAZEMETOSTAT

Dosage and treatment timings per protocol

DRUG

Zandelisib

Dosage and treatment timings per protocol

Sponsors & Collaborators

  • MEI Pharma, Inc.

    collaborator INDUSTRY

  • Jacob Soumerai, MD

    lead OTHER

Principal Investigators

  • Jacob D. Soumerai, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-31
Primary Completion
2024-12-01
Completion
2026-12-01
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05604417 on ClinicalTrials.gov